|Bid||2.4100 x 4000|
|Ask||2.4200 x 2900|
|Day's Range||2.3900 - 2.4800|
|52 Week Range||2.3400 - 13.7100|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.